Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-(Benzyloxy)Pyridin-2-Amine is a synthetic small molecule belonging to the aminopyridines class. It has been studied as an experimental compound and is not approved for clinical use. Its primary known mechanisms of action are as an inhibitor of mitogen-activated protein kinase 14 (MAPK14, also known as p38 alpha MAP kinase) and leukotriene A4 hydrolase. These targets suggest potential anti-inflammatory or immunomodulatory effects, but there are no approved indications or advanced clinical trials reported for this compound[1][9]. The molecule is primarily used in research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(Benzyloxy)Pyridin-2-Amine.